Riskpilot← Back to searchSign inGet full accessSYNACT PHARMA ApS
APSActiveCVR 34459975Dronninggårds Alle 136Manufacture of pharmaceutical preparations · NACE 2120Est. 20126 employees
Revenue 2024
DKK -26,3M
-59% vs 2023
EBITDA margin
131.6%
+50% vs 2023
Equity ratio
66.4%
Financial strength
Net profit 2024
DKK -30,5M
+53% vs 2023
| Revenue | DKK -26,3M | -59% |
| EBITDA | DKK -34,6M | +50% |
| Net profit | DKK -30,5M | +53% |
| Total assets | DKK 37,8M | +41% |
| Equity | DKK 25,1M | +61% |
| Employees | 6 | — |
Legal name
SYNACT PHARMA ApS
CVR number
34459975
Legal form
Anpartsselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
14. marts 2012
Share capital
DKK 1.000.000
Employees
6 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af to direktører i forening.
Company purpose
Selskabets formål er at udvikle lægemidler og dermed relateret virksomhed samt enhver aktivitet, der efter direktionens skøn står i forbindelse hermed.
Address
Dronninggårds Alle 136
Phone
+4528447567
Email
joo@txppharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -1.973 | -953 | -343 | -309 | -9.885 | -9.992 | -16.810 | -11.468 | -16.676 | -43.430 | -46.951 | -63.448 | -26.275 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -2.647 | -7.454 | -6.410 | -8.310 |
| EBITDA | -2.007 | -1.021 | -412 | -309 | -9.885 | -9.992 | -16.810 | -11.468 | -16.676 | -46.077 | -54.405 | -69.858 | -34.585 |
| Depreciation & amort. | -0 | -0 | -0 | -68 | -169 | -194 | -221 | -239 | -286 | -472 | -817 | -1.011 | -1.449 |
| EBIT | -2.007 | -1.021 | -412 | -377 | -10.053 | -10.186 | -17.030 | -11.707 | -16.963 | -46.550 | -55.222 | -70.869 | -36.035 |
| Net financials | -43 | -233 | -374 | -439 | -49 | -115 | -104 | -338 | -419 | -109 | -58 | -40 | 57 |
| Profit before tax | -2.051 | -1.254 | -786 | -817 | -10.102 | -10.300 | -17.135 | -12.045 | -17.381 | -46.658 | -55.280 | -70.909 | -35.977 |
| Tax | -293 | -192 | -18 | -34 | -1.218 | -2.021 | -3.487 | -2.219 | -3.379 | -5.502 | -5.500 | -5.500 | -5.500 |
| Net profit | -1.758 | -1.061 | -768 | -783 | -8.885 | -8.279 | -13.647 | -9.826 | -14.002 | -41.157 | -49.780 | -65.409 | -30.477 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1.923 | 1.239 | 568 | 306 | 21.260 | 10.091 | 7.399 | 6.076 | 12.691 | 13.544 | 37.947 | 26.785 | 37.792 |
| Equity | — | -2.342 | -3.110 | -3.893 | 9.925 | 1.647 | -12.001 | -21.827 | 11.357 | 6.649 | 33.995 | 15.586 | 25.109 |
| Long-term debt | 1.394 | 3.227 | 3.615 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 1.809 | 353 | 64 | 46 | 11.335 | 8.444 | 19.399 | 27.903 | 1.334 | 6.895 | 3.852 | 7.172 | 11.327 |
| Total debt | 3.203 | 3.581 | 3.679 | 4.199 | 11.335 | 8.444 | 19.399 | 27.903 | 1.334 | 6.895 | 3.852 | 7.172 | 11.327 |
EBITDA margin
-3458523300.0%
This company
15.8%
Market median
-21889388075% vs market
20122024
Equity ratio
66.4%
This company
38.2%
Market median
+74% vs market
20122024
Return on equity
-121.4%
This company
18.4%
Market median
-760% vs market
20122024
Net profit margin
-3047737600.0%
This company
8.1%
Market median
-37626390223% vs market
20122024
Asset turnover
-0.70×
This company
1.12×
Market median
-163% vs market
20122024
Debt / equity
0.51×
This company
0.62×
Market median
+18% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-03-14 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
BU Management | Management | 2023 | — | — |
HS Management | Management | 2016 | — | — |
TB Management | Management | 2023 | — | — |
PR Management | Management | 2022 | — | — |
JØ Chief Executive Officer | Chief Executive Officer | 2024 | — | — |
TB Chief Executive Officer | Chief Executive Officer | 2023 | — | — |
BS | Audit | 2012 | — | — |
SG Chief Executive Officer | Chief Executive Officer | 2012 | — | — |
AK Management | Management | 2026 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2015 | — | — | |
| Chairman | 2013 | — | — | |
| Board of Directors | 2013 | — | — | |
| Board of Directors | 2015 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2016 | |
| Individual | 10.0% | 10.0% | 2016 | |
Next Stage Ventures ApS | Company | 5.0% | 5.0% | 2016 |
TJ BIOTECH HOLDING ApS | Company | 33.3% | 33.3% | 2016 |
Uddannelses- og Forsknings- ministeriet | Company | 25.0% | 25.0% | 2012 |
QUANTASS ApS | Company | 25.0% | 25.0% | 2016 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of SYNACT PHARMA ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Björn Uno Bernhard Westberg | Management | 0 companies |
| Henrik Stage | Management | 0 companies |
| Thomas Boesen | Management | 0 companies |
| Patrik Renblad | Management | 0 companies |
| Jeppe Øvli Øvlesen | Chief Executive Officer | 0 companies |
| Torbjørn Bjerke | Chief Executive Officer | 0 companies |
| Bruno Sten Rosenkrans Jensen | Audit | 0 companies |
| Sigbjørn Georg Nielsen Kjærgård | Chief Executive Officer | 0 companies |
| Ann Kristin Brøgger Led | Management | 0 companies |
| Otto Bjerg Hausgaard | Chairman | 0 companies |
| Uli Alf Hacksell | Chairman | 0 companies |
| Jørn Frederik Falch | Board of Directors | 0 companies |
| Thomas Engelbrecht Nordkild Jonassen | Board of Directors | 0 companies |